Seeking Alpha

More on Merck (MRK) Q4 earnings: Q4 sales of $11.7B off 5% Y/Y, with 2% due to impact of...

More on Merck (MRK) Q4 earnings: Q4 sales of $11.7B off 5% Y/Y, with 2% due to impact of exchange rates. Impact of August 2012 loss of market exclusivity for Singulair: Q4 sales of $480M, -67.8% Y/Y. Januvia sales of $1.13B, +15.3% Y/Y. FY2013 non-GAAP EPS guidance of $3.60-$3.70 inline with consensus. Shares +0.7% premarket. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|